iRhythm(US:IRTC)2025-05-01 22:44Financial Performance & Guidance - iRhythm Technologies reported first quarter 2025 revenue of $158.7 million, a 20.3% increase compared to the first quarter of 2024[8] - The company's gross profit margin for the first quarter of 2025 was 68.8%[42] - Adjusted operating expenses for the first quarter of 2025 were $140.4 million[42] - The adjusted EBITDA margin for the first quarter of 2025 was -1.7%[42] - The company updated its 2025 annual revenue guidance to $690 - $700 million and adjusted EBITDA margin to 7.5% - 8.5% of revenue[46] Market Opportunity & Expansion - The company estimates a potential market of over 27 million patients in the United States who could benefit from ambulatory cardiac monitoring[10] - There is a target market opportunity of over 5 million tests across prioritized EU and APAC countries[10] - The company estimates over 30% penetration in the core U S ambulatory cardiac monitoring market as of March 31, 2025[13] - The international market represents a $1+ billion total addressable market (TAM) with 5+ million tests in prioritized countries across EMEA and Asia Pacific[36] Technology & Clinical Data - The company has accumulated over 2.5 billion hours of curated ECG data since its inception through 2024[15]